Can Medicare cover Wegovy or Zepbound for weight loss in 2026?

Short answer: yes, but only in a narrow, temporary way. Starting July 1, 2026, some Medicare Part D enrollees may get Wegovy or Zepbound for weight loss through CMS‘s Medicare GLP-1 Bridge. It is scheduled to run through December 31, 2027. It is not broad, routine Medicare coverage for obesity drugs.

What the bridge is

CMS says the bridge is a nationwide demonstration for certain Medicare drug plans. It is meant for people whose GLP-1 use is solely for weight loss or maintaining weight loss, not for another covered medical use.

Medicare.gov says eligible requests will need prior authorization, and that authorization can cover refills and dose changes through the end of 2027 unless the patient switches to a different GLP-1.

Who may qualify

Eligibility depends on Medicare drug coverage and on CMS clinical criteria tied to body mass index and certain obesity-related conditions. CMS says the program is not open-ended and that plans must verify the details before coverage begins.

Prior authorization is required, and CMS says requests will not be accepted or processed before July 1, 2026.

What the $50 copay means

If a beneficiary qualifies, the bridge uses a flat $50 monthly copay for a one-month supply. But CMS says the bridge runs outside the normal Part D payment flow, so the $50 does not count toward the Part D deductible or the yearly out-of-pocket limit. Low-income cost-sharing subsidies do not apply to this copay.

What the program does not do

The bridge does not create broad Medicare coverage for anyone who wants a weight-loss prescription. It also does not replace Part D coverage when the same medicine is being used for another covered indication. CMS points to examples such as Wegovy for reducing major cardiovascular events in certain adults and Zepbound for obstructive sleep apnea.

What is still uncertain after 2027

The biggest open question is what happens after December 31, 2027. KFF notes that CMS has delayed the longer-term BALANCE model and extended the bridge instead, but there is still no permanent, across-the-board Medicare benefit for weight-loss GLP-1 use after the bridge ends.

What readers can do now

Check your Medicare drug coverage and plan type.
Ask your prescriber whether your use fits the bridge’s weight-loss criteria or a separate covered indication.
Expect prior authorization paperwork.
Do not assume the $50 copay will count toward normal Part D spending limits.
If you have questions about your plan or eligibility, Medicare.gov says beneficiaries can call 1-800-MEDICARE.

Coverage is separate from medical suitability. The FDA label for Wegovy carries a boxed warning about thyroid C-cell tumors seen in animals and warns about serious risks such as pancreatitis and gallbladder problems. People should not start, stop, or change a GLP-1 drug based on coverage news alone.

Bottom line: Medicare can help cover Wegovy or Zepbound for weight loss in 2026 for some beneficiaries, but only through the temporary CMS bridge and only if they meet the program’s rules.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.